Floatz logo

ct-868

Obesity Disorder

Carmot Therapeutics, Inc.UNKNOWNPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

464 Active assets in the Obesity Disorder cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
Royal North Shore Hospital
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Survodutide
Boehringer Ingelheim
Phase 3BBB

View all 50 →

Same molecule, other indications

ct-868 is also rated in:

type 1 diabetes mellitusActive
BB
Indicative · Phase 2
64 / 100
View asset →
type 2 diabetes mellitusActive
B
Indicative · Phase 2
57 / 100
View asset →
diabetes mellitusDormant
CC
Indicative · Phase 1
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →